Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products.
Total raised: $216M
Investors 8
Funding Rounds 3
| Date | Series | Amount | Investors |
| 24.03.2020 | Series C | $123M | - |
| 08.08.2018 | Series B | $73M | - |
| 08.08.2013 | Series A | $20M | - |
Mentions in press and media 15
| Date | Title | Description |
| 24.01.2023 | Apexigen Announces Approximately $2.8 Million Private Placement Financing | - |
| 09.04.2021 | Apexigen Announces Presentations Of Preclinical Data For Its TNFR2 Antagonist (APX601) And SIRPα Antagonist (APX701) Programs At The AACR Annual Meeting 2021 | |
| 09.11.2020 | Apexigen Announces First Preclinical Data Presentations On Novel Anti-TNFR2 And Anti-SIRPα Antibody Programs At The 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting | |
| 24.03.2020 | Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline | - |
| 24.03.2020 | Apexigen Pulls In $65M Series C Financing | SAN CARLOS, CA, Apexigen today announced the completion of a $65 million equity financing. >> Click here for more funding data on Apexigen >> To export Apexigen funding data to PDF and Excel, click here Apexigen, a clinic... |
| 24.03.2020 | Apexigen Closes $123M Series C Financing Round | Apexigen, Inc., a San Carlos, Calif.-based clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, completed a $65m equity financing. The round was led by Dechen... |
| 10.08.2018 | Term Sheet — Friday, August 10 | MORE DEBT Happy Friday, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop According to the WSJ, the note, which accrues interest of 2.8% a year starting next September, gives WeWork the ability to foc... |
| 09.08.2018 | Apexigen Secures $73M | SAN CARLOS, CA, Apexigen today announced the successful completion of its Series B and Series C financings in which it raised a total of $73 million. >> Click here for more funding data on Apexigen >> To export Apexigen fund... |
| 08.08.2018 | Apexigen Raises $73M in Series B And Series C Financings | Apexigen, Inc., a San Carlos, Calif.-based clinical-stage biopharmaceutical company, completed its Series B and Series C financings in which it raised a total of $73m. The $15m Series B financing was led by Decheng Capital while the recent ... |
| 08.08.2013 | Apexigen Closes $20M Series A1 Financing | Apexigen, a Burlingame, Calif.-based biopharmaceutical company, closed $20m a Series A1 financing. The round was led by Amkey Ventures, with participation from WSR Capital, China Development Industrial Bank, Themes Investment Partners and S... |
Show more